Transcript Highlights:

• last two attorney generals, they'll tell you they've collected over a billion dollars from our pharmaceutical
• You know, we simply have got to stop trading one addictive compound for another addictive compound.
• It is a botanical compound, meaning it's just a naturally occurring compound that is found in the root
• 54.320><c> this</c><01:42:54.480><c> preparation</c> Doing some research on this preparation, or this compound

Keywords: 1. Call to Order and Roll Call – 00:00:00 2. Approval of Minutes – 00:01:32 3. Getting to Know the Foundation for a Healthy Kentucky – 00:02:26 4. Healthy Kids Clinic – 00:26:58 5. Pharmacy Payment Parity – 00:56:36 6. Ibogaine – 01:17:37 7. Consideration of Referred Administrative Regulations – 01:53:05 8. Adjournment – 01:53:19, 958, all

Summary: The committee first approved the prior meeting minutes and recognized Eric Clark for his service, noting this may be his last meeting before he leaves state government. The main presentation was from Allison Adams, president and CEO of the Foundation for a Healthy Kentucky, who described the organization’s history, nonpartisan mission, and focus on health equity, prevention, and upstream policy solutions. She said Kentucky’s poor rankings in chronic disease, preventable hospitalizations, and life expectancy show the need to shift resources toward prevention and community-driven strategies rather than relying mainly on treatment after people become sick. Adams emphasized leading health indicators, arguing that lawmakers should track actionable measures such as quit attempts and smoke-free policies instead of only lagging indicators like disease rates and mortality. In response to questions, she said accountability should be shared across communities and systems, with possible incentives and disincentives tied to outcomes, and she supported creating a public data utility or dashboard, ideally with university partners, to help legislators and communities monitor progress. She also cited examples of accountable health community models and said Kentucky could adapt similar approaches. The committee then heard from Meade County Schools Superintendent Mark Martin and district health coordinator Karen Kotche about the Healthy Kids Clinic partnership with Cumberland Health. They described a seven-year effort that led to full implementation in the district, which now has a nurse in every school and a nurse practitioner, allowing services such as sports physicals and other clinic functions to be provided on campus. They said the program has been a strong investment for students and the community and began explaining how the district built the partnership after earlier efforts and delays, including the pandemic.

Transcript Highlights:

• Your pharmaceutical used to only be 10 to 12% of the health care dollar.
• Phil Christophernelly here on behalf of the Pharmaceutical Care Management Association.
• I represent the Pharmaceutical Care Management Association.
• I represent the Pharmaceutical Care Management Association.
• Large pharmaceutical manufacturers. You know their names.

Summary: The committee first adopted the minutes from several prior 2025 meetings, then took up HB 574 by Rep. Spell, which updates the names of two organizations on the Mental Health Advocacy Service Board of Trustees. Rep. Spell explained it as a technical cleanup bill to correct the names of the Louisiana Mental Health Association and the Louisiana State Medical Society so the board’s membership records match current organization names. With no objections, HB 574 was reported favorably. The committee then heard HB 486, also by Rep. Spell, to join the Psychology Interjurisdictional Compact (PsyPact) and allow Louisiana psychologists to provide telepsychology and temporary in-person services across state lines. Rep. Spell and PsyPact representatives said the compact would expand access to mental health care, especially in rural areas, while maintaining standards and disciplinary oversight. The committee adopted amendments on fees and the effective date, and HB 486 was reported favorably with amendments. HB 198 by Rep. Eccles proposed a Medicaid reimbursement methodology for ambulatory surgical centers, using a Medicare-based rate to improve access for Medicaid patients needing specialty procedures. Amendments were adopted to add ophthalmology-related services and to cap reimbursement at the lesser of the outpatient hospital rate or 100% of the Medicaid rate, along with a technical amendment to address the fiscal note. Supporters from GI and ASC groups said the bill would improve access and lower long-term costs, and the bill was reported favorably with amendments. The committee spent the most time on HB 182 by Rep. Travis Johnson, which would require hospitals to ensure access to sexual assault forensic exams and related training. Johnson, law enforcement witnesses, and the Attorney General’s office emphasized the need for timely evidence collection, especially in rural areas, and said the current system leaves victims traveling long distances or losing evidence. Hospital and coroner witnesses supported the goal but opposed the bill as written, arguing it could impose duties on hospitals without enough trained personnel, funding, or a workable statewide training and coordination system; they urged a statewide coordinator, mobile SANE units, and clearer implementation. The bill was not finally disposed of in the portion of the meeting provided, and members discussed continuing to work on amendments and timing before floor consideration.

Transcript Highlights:

• Insurance is blaming pharmaceutical and also the hospitals.
• We're blaming the pharmaceuticals and the insurance industry.
• Insurance is blaming pharmaceutical and also the hospitals.
• We're blaming the pharmaceuticals and the insurance industry.
• Is there any change from the rest of the population in pharmaceuticals?

Keywords: 908, all

Summary: The committee met to review the history and current treatment of North Dakota health insurance mandates, with presentations from Blue Cross Blue Shield of North Dakota, Sanford Health Plan, the Public Employees Retirement System (PERS), and the Insurance Department. The discussion focused on how mandates apply differently to fully insured, self-funded, ACA, Medicaid, and PERS plans; how the state’s benchmark plan and federal essential health benefits affect coverage; and how the existing process requires cost-benefit analysis and, for certain measures, a PERS pilot period before broader application. Presenters also reviewed the long list of existing state mandates, including provider, beneficiary, and coverage requirements, and noted that many were enacted decades ago and have not been revisited despite changes in medical evidence and treatment options. Witnesses from the carriers argued that mandates should be reviewed periodically because some are outdated, can create unintended costs, and may not align with current medical guidance. Examples cited included PSA screening, off-label drug coverage, prior authorization rules, step therapy, and cost-sharing provisions for mental health and substance use treatment. They emphasized that carriers often cover services without a mandate when supported by clinical evidence, and that mandates can shift costs to employers and employees, especially in the fully insured small-group market. They also suggested possible policy improvements such as clearer mandate definitions, better transparency around cost-benefit analyses, a regular 10-year review of mandates, and more timely submission of proposals through the interim process. PERS and the Insurance Department highlighted a recurring tension over what counts as a mandate and when a measure triggers the state’s defrayal obligation under federal law. PERS described its interim committee process, the April 1 deadline for fiscal-impact proposals, and the limited pilot program used for certain measures, noting that only a few bills have gone through the full pilot process. The Insurance Department explained that it views new benefit mandates through the lens of the ACA benchmark plan and essential health benefits, distinguishing true new benefits, such as infertility coverage, from changes to existing benefits, such as telehealth or insulin cost-sharing caps. No votes were taken on policy changes; the meeting was informational, with members asking questions about costs, applicability, transparency, and whether a periodic mandate review should be established.

Transcript Highlights:

• requiring prescription drug manufacturers to notify the Attorney General of arrangements between pharmaceutical
• requiring prescription drug manufacturers to notify the Attorney General of arrangements between pharmaceutical

Keywords: 993, senate, all

Summary: The Senate Standing Committee on Consumer Protection held its first meeting of the year on January 28, chaired by Senator Rachel May, with Ranking Member Patricia Canzoneri-Fitzpatrick and several other senators present. Chair May said the committee would focus this session on consumer protection issues such as surveillance pricing and the use of technology to target consumers unfairly. The ranking member briefly agreed on the importance of protecting vulnerable consumers and wished the committee a successful session. The committee then considered six bills, all of which had previously passed the Senate. The measures covered school security guards (S.194B), notice to the Attorney General about arrangements that delay generic drug introductions (S.488A), warranties and protections for purchasers of new and used motor vehicles (S.5597), a cap on credit service charges in retail installment contracts (S.5600), requirements for rental helmets to address concerns about damaged helmets (S.6985), and making renewed appearance enhancement and barber licenses and certificates available online in downloadable PDF form (S.7483). There was little discussion on most bills, though Senator May noted that the helmet bill was intended to address situations where rented helmets may have been damaged or consumers may not know their condition. Each bill was moved, seconded, and approved by the committee without opposition, with one bill reported to the Finance Committee and the others reported to first reading on the calendar. The meeting then adjourned after concluding legislative business.

Transcript Highlights:

• History reveals vaccine agendas are often funded by pharmaceutical companies, so we're following the
• </c><01:49:06.400><c> companies</c><01:49:06.800><c> so</c> funded by pharmaceutical companies so funded
• </c> biology anatomy And even Pharmaceuticals biology anatomy And even Pharmaceuticals with<03:42:35.159
• We the people need you to stand on our side and not on the side of a big pharmaceutical company that
• </c><03:43:31.920><c> company</c> the side of a big pharmaceutical company the side of a big pharmaceutical

Keywords: 910, house, all

Summary: The House Committee on Judiciary and Hawaiian Affairs heard several measures, beginning with HB 194, which would designate May 22 as Maritime Day. Testimony from labor, health, and community groups was in support, and the committee later recommended passage of the bill as is, with several members voting yes and some reserving or being excused. HB 458 would designate April 27 as Brother Joseph Dutton Day; the Department of Accounting and General Services, the Joseph Dutton Guild, and a descendant all supported it, and the committee recommended passage with technical amendments. HB 957 would designate the first Friday in May as Lā‘au Day; support came from the Office of Hawaiian Affairs, the Hawaii Farm Bureau, and many individuals, and the committee recommended passage as is. HB 345 would establish the ʻōpae ula as the state shrimp to promote awareness and protection of anchialine ecosystems; DLNR, Kuaʻāina Ulu ʻAu, and other supporters testified, and the committee recommended passage with technical amendments. The committee also heard HB 901, which would allow public charter schools to appeal directly to the Board of Education on certain operational, governance, or funding matters. The Attorney General and the Public Charter School Commission offered technical comments and suggested amendments, while the commission described its current monitoring and renewal process and said it works closely with schools over the life of a charter contract. Members raised concerns about whether the bill would shift too much work to the Board of Education, and one member voted no when the committee later moved the bill with the Attorney General’s amendments. HB 1066 would add Head Start-related ex officio members to the Early Learning Board; the Early Learning Board and the Executive Office on Early Learning supported it, explaining the changes were needed to align with the federal Head Start Act, and the committee moved it forward without opposition. HB 1069 would add voting members from the Department of Education and Board of Education to the School Facilities Authority Board. DOE and the School Facilities Authority supported the change as a way to strengthen collaboration, though questions from members focused on the current communication process between the agencies. HB 1343 would require the Board of Education to adopt a policy banning student phone and related device use during school hours; the committee noted written testimony in support and then moved to decision-making. At the end of the meeting, the committee adopted recommendations to pass HB 194, HB 458 with technical amendments, HB 957, HB 345 with technical amendments, HB 901 with amendments, HB 1066, HB 1069, and HB 1343.

Transcript Highlights:

• So, whatever money the state puts in, the pharmaceutical or drug company would have to match it.
• So, whatever money the state puts in, the pharmaceutical or drug company would have to match it.
• So, whatever money the state puts in, the pharmaceutical or drug company would have to match it.
• :31:17.120><c> putting</c> have a partner pharmaceuticals putting have a partner pharmaceuticals putting
• I'm just interested in why do we need a law because pharmaceutical companies do it all the time.

Keywords: MS House Floor - 21 January, 2026; 2:00 PM, 925, all

Transcript Highlights:

• know what the difference between, I guess, the whole-leaf kratom and the 7-OH, like that active pharmaceutical
• And the 7-OH, like that active pharmaceutical ingredient, whatever that opioid is.
• concomitant use of other substances, including alcohol, opioids such as fentanyl, barbiturates, pharmaceuticals
• Can you give me what that ratio looks like for, you know, what that active pharmaceutical ingredient,

Summary: The House Health and Welfare Committee heard testimony on House Bill 864, which would classify kratom and related substances as Schedule I drugs. Sponsor Rep. Mike Pohanka and co-sponsor Rep. Aaron Bingham argued the bill was needed for public safety, citing reports from law enforcement, families, coroners, and medical professionals about addiction, overdoses, and deaths they attributed to kratom, along with concerns about synthetic 7-OH products. Supporters included the Bonneville County sheriff and coroner, who said they were seeing kratom-related deaths, youth exposure, and limited enforcement tools under current law. Opponents and those urging a regulatory approach said natural leaf kratom has helped with chronic pain, opioid recovery, and quality of life, and that a full ban would push users to black markets or more dangerous substances. Several retailers, consumers, and a toxicologist distinguished between traditional leaf kratom and concentrated or synthetic 7-OH products, arguing that the latter should be targeted instead of banning all kratom. A family physician and treatment provider said kratom use disorder and withdrawals were real and increasing, but cautioned that an abrupt ban could create unintended harms and recommended labeling, age limits, and product testing instead. Committee members asked questions about the difference between natural kratom and 7-OH, the evidence behind overdose and death claims, and whether a Schedule I classification would eliminate medical access. After hearing from a long list of testifiers, the chair said the committee had only reached partway through the sign-up list and asked whether to continue another day. Members agreed to resume testimony the next morning from 8 to 9 a.m., and the meeting adjourned without a vote on the bill.

Transcript Highlights:

• Were they on pharmaceutical drugs? Were they on illicit or illegal drugs?
• If we find that illegal substances or pharmaceuticals are not, I don't know.
• That illegal substances or pharmaceuticals are not a major component, then we can settle that element
• we have not been looking at the potential impact of illegal and illicit substances as well as pharmaceutical

Keywords: 988, house, all

Transcript Highlights:

• on behalf of health plans, employers, and other payers, PBMs extract billions of dollars from pharmaceutical
• So you have drug manufacturers, so like pharmaceutical companies, and I'm not trying to be condescending
• But I know that this is how I kind of learned how this process worked: you have pharmaceutical companies
• They administer pharmaceutical benefits for health plans. They create formularies.

Bills: AB93, AB204, AB414, AB504, AB598

Keywords: public employees, police officers, benefits, appropriation, law enforcement, medical debt, collection agency, healthcare, consumer protection, financial assistance, occupational safety, air quality, greenhouse gases, employee monitoring, safety program, hemp, hemp products, cannabidiol, CBD, cannabis

Transcript Highlights:

• around how people can use therapeutic cannabis and get off of pharmaceuticals.
• </c><00:52:24.000><c> rebates</c> this Ryan White pharmaceutical rebates this Ryan White pharmaceutical
• </c><02:53:57.000><c> companies</c> work with the pharmaceutical companies work with the pharmaceutical
• As you can imagine, these are really sensitive pharmaceutical products.
• sensitive pharmaceutical products sensitive pharmaceutical products they've<03:04:13.920><c> got</c><

Keywords: 928, house, all

Summary: The Finance Division III work session focused on the Department of Health and Human Services’ Division of Public Health Services budget. Department staff said Public Health has a relatively small budget compared with other DHHS divisions, is supported mostly by federal and other non-General funds, and contains nearly 100 accounting units and more than 50 federal grants. They emphasized that the governor’s budget did not include significant cuts, but that federal funding uncertainty and the winding down of pandemic-era resources were major factors affecting the division. The division also explained that some apparent budget growth reflects reorganizations, including moving the Bureau of Emergency Preparedness, Response, and Recovery and some programs from other DHHS divisions into Public Health. The presentation described Public Health’s mission as serving the entire state through food and water safety, disease surveillance, emergency response, maternal and child health, chronic disease prevention, WIC, community health center support, and public health data collection. Members asked about bird flu, and staff explained that human-health response would involve Public Health’s lab, infectious disease, and emergency preparedness units, while animal-health issues are handled with the Department of Agriculture; they also noted ongoing milk testing requested by FDA and USDA. The division said its organizational structure includes bureaus for Family Health and Nutrition, Infectious Disease Control, Public Health Protection, Emergency Preparedness, Prevention and Wellness, Statistics and Informatics, and Public Health Laboratories, with about a 15% vacancy rate. Committee members questioned whether the division’s budget and staffing had really grown since pre-COVID, and staff responded that full-time authorized staffing is about the same as in 2018, with the increase largely due to federal pandemic funding that has since receded and to program transfers between divisions. They said Public Health’s General Fund share is about $24 million out of roughly $1.1 billion in DHHS General Fund spending, or about 2.2% of the department total. Members also asked about the 3,000-position cap and unfunded positions; staff explained that the cap remains in chapter law through June 30, 2025, that 394 positions were unfunded in the governor’s budget, and that the division expects flexibility to move money from personnel lines and fill unfunded positions to manage changing needs. No votes or formal actions were taken in this portion of the work session.

Transcript Highlights:

• Um, but to the extent these pharmaceuticals are helpful to people who need them, I think we would like
• Next up, we have the pharmaceutical manufacturers perspective. We have Tracy Sims.
• Next up, we have the pharmaceutical<00:29:49.919><c> manufacturers</c> pharmaceutical manufacturers pharmaceutical
• And certainly pharmaceuticals is a big component of this.
• :51.680><c> is</c><01:00:51.839><c> a</c> And certainly pharmaceuticals is is a And certainly pharmaceuticals

Keywords: 958, all

Summary: The Medicaid Oversight and Advisory Board met on February 23, 2026, approved the January 12 minutes, and then focused primarily on Kentucky Medicaid’s coverage and potential expansion of GLP-1 drugs, especially for weight loss. Department for Medicaid Services Commissioner Lisa Lee explained that Medicaid currently does not cover drugs for weight loss, anorexia, or weight gain, but the department had filed a regulation to remove that blanket exclusion so GLP-1s could be covered when used for an underlying health condition. She said the administrative regulation review subcommittee found the regulation deficient, and the co-chairs wanted the board to discuss the policy and financing implications before any change. DMS also said it would be open to adding caveats to ensure coverage would not extend to cosmetic weight loss alone. The department provided several data points on current utilization and spending. In 2025, Kentucky Medicaid paid for appetite-stimulating drugs such as Megestrol, Dronabinol, and Marinol, but did not pay for weight-loss drugs. For GLP-1s, DMS said coverage began in 2025 and is limited to FDA-approved medical conditions, with prior authorization requiring a type 2 diabetes diagnosis code and A1C documentation. DMS reported $234.6 million in GLP-1 spending in 2025 before rebates, about 240,931 prescriptions, and said GLP-1s accounted for 7.3% of pharmacy spend in 2024 and 8.3% in 2025. It also said there were 24,844 expansion members and 13,638 non-expansion members using GLP-1s, with spending of about $156 million and $78.5 million respectively, and that 10 pediatric weight-loss prescriptions were covered under EPSDT. The department said outcome analyses, including whether GLP-1 use reduces insulin or other diabetes treatment, are underway and should be completed in a couple of months. Members asked about cost, rebates, and whether the state should wait for more outcomes data before expanding coverage. DMS said average reimbursement to pharmacies was $975 per prescription and the average dispensing fee was $109; it also said 2025 rebate invoices totaled $90.8 million, with $7.6 million collected so far. Several members expressed concern about the high cost and the need to evaluate whether the drugs improve health outcomes before expanding access, while others noted the potential benefits for obesity and diabetes treatment. Some members also discussed whether GLP-1s are effectively being used for weight loss in diabetic patients and whether broader data collection should be used to assess long-term value. After the Medicaid discussion, Eli Lilly executive Tracy Sims presented on obesity as a chronic disease and the economic burden it creates in Kentucky. She said Kentucky’s adult obesity rate is a little over 37%, that obesity is linked to about 200 diseases, and that untreated obesity costs the state billions in GDP and hundreds of millions in state budget impact. She highlighted recent federal access programs for GLP-1s, including a Medicaid-related program that she said could lower the state share of a Zepbound prescription to about $71 per month after federal matching. No votes were taken on the GLP-1 policy question during the meeting, and the main action was the receipt of testimony and discussion of the department’s proposed regulatory change.

Transcript Highlights:

• Um, you know, similar to that pharmaceuticals?
• It's more complicated to do pharmaceuticals than devices. >> Um, but I don't know.
• The only caveat is they don’t provide pharmaceuticals and if... ...provide pharmaceuticals, and that
• My ill-informed instinct is that we don't start with pharmaceuticals.
• Um, and look for feedback from anybody who's paying attention about pharmaceuticals.

Keywords: 916, all

Transcript Highlights:

• Let's say it's a pharmaceutical company. Then NAMFCU will create a team that will prosecute it.
• Let's say it's a pharmaceutical company. Then NAMFCU will create a team that will prosecute it.
• </c> likely just like the pharmaceuticals likely just like the pharmaceuticals come<00:37:23.520><c>
• They could be substituting pharmaceutical types. They could be generic.
• They could be substituting pharmaceutical types. They could be generic.

Keywords: 1189, house, all

Summary: The committee chair opened by explaining that the committee has expanded from a traditional audit-follow-up role into an oversight role focused on whether audit recommendations are implemented and whether controls are in place to detect fraud. He said the committee was concerned about fraud uncovered in social service programs in other states and wanted to understand New Hampshire’s safeguards, especially around major contracts and program performance. Charles Buchanan, director of the New Hampshire Medicaid Fraud Control Unit, and investigator Tim Brackett described the unit’s structure and mission. Buchanan said the unit, housed in the Attorney General’s Criminal Justice Bureau, investigates and prosecutes fraud by health care providers serving Medicaid beneficiaries, as well as abuse, neglect, and financial exploitation of residents in health care facilities. He outlined common Medicaid fraud schemes such as billing for services not rendered, upcoding, using unqualified staff, drug substitution, kickbacks, supplemental charges, and inflated customary charges. He also described resident abuse/neglect and drug diversion in hospitals, nursing homes, and assisted living settings. Brackett said his role is financial investigator/auditor and noted the unit is grant-funded and must include a prosecutor, investigator, and auditor. The witnesses then explained how cases reach the unit and how they are handled. Most referrals come from the state Department of Health and Human Services’ program integrity unit and from managed care organizations’ special investigations units, which look for fraud, waste, and abuse and refer credible allegations. Other sources include qui tam whistleblower actions, the national Medicaid Fraud Control Units association, citizen complaints, provider referrals, adult protective services law-enforcement referrals, local law enforcement, and federal agencies. Once a referral is received, the unit can accept or deny it; accepted matters may be investigated criminally or civilly, while nonviable matters can be referred back to HHS or other agencies for administrative action, including repayment demands and reimbursement offsets. No votes or formal committee actions were taken in the portion provided.

Transcript Highlights:

• So these companies, whether it be pharmaceutical, cosmetics, or food companies, I heard a great senator
• He believed that if they passed this and a pharmaceutical company sued, Idaho would get preempted immediately
• He believed that if they passed it and a pharmaceutical company sued, Idaho would be preempted immediately
• And I think the second we passed this, and a pharmaceutical company sued us, Idaho would get preempted

Keywords: 989, all

Summary: The Senate Commerce Committee approved the February 24, 2026 minutes and then considered a gubernatorial reappointment of Jeff Seilich to the Public Employee Retirement System of Idaho (PERSI) board. Seilich told the committee PERSI remains stable and well funded, and members praised his service; the committee said it would likely vote on the reappointment later in the week. The committee then advanced House Bill 543, a technical PERSI bill updating language to comply with federal Secure Act 2.0 by changing references from after-tax contributions to Roth-type contributions in the PERSI Choice Plan. Representative Ben Furman and PERSI Director Mike Hampton described it as a narrow compliance fix, and the committee voted unanimously to send the bill to the Senate floor with a due pass recommendation. House Bill 563, which revises CPA licensing requirements, also received a due pass recommendation. Representative Jeff Ehlers and Idaho Society of CPAs representatives said the bill is intended to address a shortage in the profession by creating three pathways to licensure, including options with fewer education hours but more experience, while keeping the CPA exam requirement and easing reciprocity for out-of-state CPAs. The committee voted to send the bill to the floor. The committee spent the most time on Senate Bill 1310, the Human Fetal Tissue Transparency Act, which would require labeling for products tested or developed using human fetal tissue or related cell lines. Supporters argued the bill would improve consumer transparency and informed consent for products such as vaccines, cosmetics, and food items; opponents and several senators raised concerns about federal preemption, enforcement, costs to businesses, and whether the bill would apply to doctors, hospitals, and retailers. After debate, the committee adopted a substitute motion to hold the bill in committee by a 5-4 roll call vote, and the meeting adjourned.

Transcript Highlights:

• The USDA has approved four pharmaceuticals.
• We have two different pharmaceuticals that can be used to treat the screw worm when it comes into the
• With regards to the pharmaceuticals, the commodities, And importing box beef from foreign countries should
• Cattle that are brought into the United States are regulated with regards to the pharmaceuticals, the

Summary: The House Committee on International Trade held its first meeting of the session with member introductions and opening remarks emphasizing Arizona’s interest in foreign relations, border commerce, and collaboration with trading partners, especially Mexico. Chair Tony Rivera noted the state’s trade offices in Mexico and framed the committee’s work as a way to strengthen Arizona’s international relationships. Staff were introduced, and members were reminded of amendment deadlines, though no bills were heard. The committee then heard a presentation from the Nogales-Santa Cruz County Chamber of Commerce and the Santa Cruz County Provisional Community College District. Chamber representatives described Nogales as a major gateway for trade, tourism, agriculture, and logistics, and said the region is investing in entrepreneurship support, bilingual business resources, digital and e-commerce training, and workforce development tied to mining and logistics. They also highlighted tourism promotion efforts and said infrastructure, housing, and pedestrian access at the ports of entry are major needs. Committee members asked about regulatory and infrastructure improvements, housing and health-care challenges, and tourism data. Greg Lucero of the provisional community college described the district’s unusual status, its contract with Pima College to provide instruction, and the impact of South32’s mining project on enrollment and workforce training demand. He said the district is focusing on AI, advanced manufacturing, trades, and ESL support, while working toward accreditation. Members asked about industry partnerships, certificate timelines, and programs tied to Arizona-Mexico trade. The committee also heard from Cattlemex, T4 Ranch, Arizona Cattle Feeder Association, and J.M. Fletcher Cattle Co. on the closure of the U.S.-Mexico border to live cattle imports because of New World screwworm concerns. Testimony argued that Sonora cattle are safe, that Arizona ports are strategically important, and that reopening the ports would support feedlots, packing plants, jobs, and lower beef prices. Witnesses urged a state-by-state USDA reopening, especially for Sonora, and said Arizona should not be penalized for outbreaks elsewhere in Mexico. Members asked about industry support, the effect of grazing restrictions, the future of Arizona’s livestock sector, and whether a Sonora-specific carve-out could be safely implemented. No votes or formal actions were taken.

Transcript Highlights:

• include all of them, whether it be ag sciences, which is more prevalent in southern New Mexico, or pharmaceutical
• It also includes bioscience-related distribution, drugs, and pharmaceuticals.
• I'm also the founder, president, and COO of a company called Mercury Bio that's working on a pharmaceutical
• program of my understanding is that New Mexico that the The biotech industry is ripe for expansion: pharmaceutical

Transcript Highlights:

• Chris Hansen, Alexion Pharmaceuticals, waves in support.
• Chris Hansen, Alexion Pharmaceuticals, waves in support. Lina Rojas, FSU, waves in support.

Summary: The Senate Committee on Education Postsecondary met with a quorum present and first considered CS/SB 1356, relating to the Florida Institute for Pediatric Rare Diseases. Senator Burton explained a delete-all amendment that would create the institute at Florida State University, establish the Sunshine Genetics Pilot Program for newborn screening at select sites, and form a Sunshine Genetics Consortium to coordinate researchers and clinicians. The amendment also included $5 million in recurring funding for the institute and $2 million in nonrecurring funding for the pilot program. The committee heard supportive testimony from Gavin Lambert and his mother, who described the benefits of earlier diagnosis for Friedreich’s ataxia, along with support from representatives of Alexion Pharmaceuticals, FSU, BioFlorida, and the Biotechnology Innovation Organization. Senators Berman and Harrell spoke in favor of the bill, emphasizing early detection and collaboration. The amendment was adopted, and CS/SB 1356 was reported favorably on a roll call vote. The committee then took up SB 892, which would codify the Florida State University Election Law Center in statute and make it eligible for recurring funding. Senator Simon said the center was created in 2023 with a $1 million nonrecurring appropriation and that the bill would help sustain its work and attract talent in election law and related fields. Senator Berman asked about current funding and whether the center would be supported through recurring General Appropriations Act funding in the future; Senator Simon responded that the bill would allow it to compete for recurring dollars. Jack Rowan, an FSU law student, testified in support and highlighted the center’s work, including a Bush v. Gore 25th anniversary conference. Professor Michael Morley and Lena Rojas also supported the bill. No opposition was presented, and SB 892 was reported favorably by roll call vote. The committee then adjourned.

Transcript Highlights:

• projects, and Missouri is home to some of the most important assets needed by the defense and pharmaceutical
• I mean, during COVID, India cut off our supply to critical brain cancer treatments for pharmaceuticals
• the United States Department of the Interior on the critical material side, and on the critical pharmaceutical
• Yeah, it's adding critical materials and pharmaceuticals. I guess that's what you're...
• Yeah, it's adding critical materials and pharmaceuticals. I guess that's what you mean.

Summary: The House recognized its drafters and research staff, then moved through committee reports and several conference committee reports and final passage motions. Senate Joint Resolution 87 was adopted and finally passed after debate over a provision affecting the City of St. Louis sheriff; supporters said the final version restored the original format with a minor wording change, while opponents argued it removed local voter control. The resolution passed 95-46 on both the conference report and final passage votes. Members then adopted and finally passed Senate Bill 973, a measure combining a wholesaler provision and a land bank/real estate transparency provision, with supporters describing it as consumer protection and cleanup language. Senate Bill 1421, a public safety package, was also advanced after a motion to exceed the conference differences; debate focused on clean slate provisions, masked intimidation penalties, prosecuting attorney salaries, fentanyl language, good time credit, Brianna’s Law, and a St. Louis liability provision. The conference report passed 116-18, final passage 110-25, and the emergency clause for the drone-related portion passed 136-5. The House also adopted and finally passed Senate Bills 835 and 1111, a broad package including insurance claim assignment protections, court automation updates, treatment court administration, a circuit judgeship codification, a St. Louis civil case surcharge, and anti-SLAPP protections. Senate Bill 1408, which authorizes MoDOT and the Highway Commission to consider raising rural interstate speed limits from 70 to 75 mph, was receded to the Senate version and finally passed 93-46. Senate Bill 913, extending multiple agricultural tax credits through 2033 and adding a short-line railroad credit, drew extensive debate over tax credits, budget priorities, and return on investment before the previous question was ordered and the bill passed 107-30. Finally, Senate Bill 1553 was passed, creating incentives and a grant program tied to critical minerals and pharmaceuticals to reduce reliance on foreign suppliers; supporters framed it as a jobs and national security measure, while one member raised concerns about local revenue impacts before clarifying the bill’s scope. The House then received Senate messages indicating the Senate had passed a House bill, and the session continued.

Transcript Highlights:

• This includes Pharmaceutical Benefit Manager Reform, or PBM reform, a stated priority for President Trump
• The lack of transparency into what goes on when that pill leaves the pharmaceutical company and ends
• On the other hand, Medicare Part D, the pharmaceutical part of it, the drug component, that's actually
• And one of the big problems is that private equity, pharmaceutical pricing power, device manufacturer
• I'll ask you a little bit about pharmaceuticals but you said you're going to pursue that.

Keywords: Michael Falkender, Deputy Secretary of the Treasury, IRS, taxpayer privacy, nomination process, committee hearing

Summary: The committee convened to discuss critical issues surrounding the nomination of Michael Falkender for the position of Deputy Secretary of the Treasury. This meeting included a series of remarks from committee members who expressed divergent views on Falkender's qualifications and the implications of his appointment. Senator Wyden voiced strong opposition, arguing that Falkender represents harmful policies expected to be perpetuated under the current administration, especially concerning taxpayer privacy and IRS tactics. Meanwhile, other members defended Falkender, noting his extensive experience, including a commitment to transparency in government operations if confirmed.

Transcript Highlights:

• Um, when we're looking at the spectrum of mental health care, mental health, mental illness, pharmaceutical
• Um, when we're looking at the spectrum of mental health care, mental health, mental illness, pharmaceutical
• Um, when we're looking at the spectrum of mental health care, mental health, mental illness, pharmaceutical
• Um, when we're looking at the spectrum of mental health care, mental health, mental illness, pharmaceutical
• Closing Uh, pharmaceutical drugs that people are on, you're kind of pulling together like one specific

Keywords: 1183, house